EU Innovation and Competitiveness
Program Co-Chairs Iman Barilero, Johnson & Johnson PRD, and Marie Dray, International Regulatory Affairs Group USA, opened the first plenary session with introductions, sharing their vision of what the 18th Annual DIA EuroMeeting is all about: continuing themes throughout the meeting, including pediatrics, advanced therapies, technology platform, pharmacovigilance, risk management planning, and the involvement of patient groups.
Program Co-Chairs Iman Barilero, Johnson & Johnson PRD, and Marie Dray, International Regulatory Affairs Group USA, opened the first plenary session with introductions, sharing their vision of what the 18th Annual DIA EuroMeeting is all about: continuing themes throughout the meeting, including pediatrics, advanced therapies, technology platform, pharmacovigilance, risk management planning, and the involvement of patient groups.
Marie Dray mentioned that the EuroMeeting will continue Afssaps, involve patient groups, and develop the European Forum-asking regulators questions and discussing what is optimal regulation. Iman Barilero discussed the overall theme of the current environment for innovation and competitiveness in Europe.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
